A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epi
about
Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical ImplicationsOther targeted drugs in melanomaOckham's razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancerMechanism of c-MET in Non-small Cell Lung Cancer and Its Treatment and TestingMET exon 14 deletion (METex14): finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of "40 years of wilderness" and into a clear path of regulatory approvalEffective implementation of novel MET pharmacodynamic assays in translational studies.Preclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma.Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas.Targeting MET in Lung Cancer: Will Expectations Finally Be MET?New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer.Erlotinib-based targeted dual agent versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis of 13 randomized controlled trials.The Efficacy and Risk Profile of c-Met inhibitors in Non-small Cell Lung Cancer: a Meta-analysis.Hepatocyte growth factor produced in lung fibroblasts enhances non-small cell lung cancer cell survival and tumor progression.Targeting Novel but Less Common Driver Mutations and Chromosomal Translocations in Advanced Non-Small Cell Lung Cancer.Erlotinib-based doublet targeted therapy versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis from 24 randomized controlled trialsMeta-analysis of efficacy and adverse events of erlotinib-based targeted therapies for advanced/metastatic non-small cell lung cancer.MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review.The persistent promise of combining HGF/MET and EGFR inhibition in non-small cell lung cancer.The efficacy and safety of tivantinib in the treatment of solid tumors: a systematic review and meta-analysis.An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors.Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities.Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes.[Progress of c-MET Signaling Pathway and TKIs in Non-small Cell Lung Cancer].Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib.Tivantinib added to erlotinib in nonsmall-cell lung cancer: the primary end point was not MET....Targeting MET in cancer therapy.Prognostic value of MET copy number gain in non-small-cell lung cancer: an updated meta-analysis.
P2860
Q26741318-D6C91C5B-4793-4E48-B29D-78A6A82ADEE2Q26775594-6E6C7DF1-B763-49CD-A5C8-6EF0AFF2EDC1Q28067777-678CF2B5-63F1-4323-A3D3-3E354A1DA391Q28077785-01E91D06-4721-40F6-A1DC-3564805B7783Q36427358-243A249A-B128-4DF7-8F2C-1D1469D3DDD8Q37597853-473BA3E0-23A2-4D10-A0FF-C02B407F60B4Q38782345-E6058609-9E25-445B-A15B-B535DFF6357EQ38930166-7553A3F4-D615-4FB4-A0B7-B53C1043C45EQ38994327-14777770-21FF-4DFD-BF5C-214D981C46FCQ39007500-696B535F-353E-4618-8FB1-E65926B843C9Q39538184-22B007ED-1F42-4688-BD87-F60800D05D20Q41587809-CC2C3638-0E65-4226-ADEA-B2611CD9EAEBQ42153446-1FF8C0C6-7933-4CF1-ADE7-CBB84FA615FDQ42369856-255BD783-3C35-4713-870F-F53D4A3EEE66Q42700668-D55B9984-C0E7-45D8-BC95-AD081047B096Q44669628-A63BD9A9-992C-4D45-90A0-69B0F53DA395Q45968290-5A774A5A-F3B7-4D85-A3C8-F7B7AA26F891Q46073425-EB009846-9039-4E0C-86C4-A423A65AF2DDQ47653274-BD8DA26F-1C80-4738-818A-089678C2A889Q48179589-EEE994AC-DF02-438D-BCE7-57DE87D3A0A1Q49881127-AE211C3E-FF64-4E16-BB7D-55033279FD4EQ49887893-D6C34183-0BD7-4E8B-B100-9A3CC5A4FD2EQ50345931-53AB4EAC-ABB3-421F-A9C5-67A0043F572FQ53742581-D0465F8F-1E12-4987-94B8-EBB189FE0A88Q54162899-2115F998-497F-4689-8E88-8BE77946142BQ54253251-3E64624A-DA39-4FC4-A340-6AA9EA1EF07CQ54987450-59CD3B95-6641-4D3C-A829-A5BC950155E1Q55145107-BAA3ACD8-3A8B-47F8-8330-CCDB7DC30B46
P2860
A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epi
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
A randomized, double-blind, pl ...... cancer harboring wild-type epi
@en
type
label
A randomized, double-blind, pl ...... cancer harboring wild-type epi
@en
prefLabel
A randomized, double-blind, pl ...... cancer harboring wild-type epi
@en
P2093
P2860
P356
P1433
P1476
A randomized, double-blind, pl ...... cancer harboring wild-type epi
@en
P2093
H Yoshioka
K Nakagawa
M Kurosaki
M Maemondo
N Katakami
P2860
P304
P356
10.1093/ANNONC/MDV288
P577
2015-07-07T00:00:00Z